253 related articles for article (PubMed ID: 30239009)
21. Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study.
Barthur A; Brezden-Masley C; Connelly KA; Dhir V; Chan KK; Haq R; Kirpalani A; Barfett JJ; Jimenez-Juan L; Karur GR; Deva DP; Yan AT
J Cardiovasc Magn Reson; 2017 Apr; 19(1):44. PubMed ID: 28395671
[TBL] [Abstract][Full Text] [Related]
22. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
Dang C; Guo H; Najita J; Yardley D; Marcom K; Albain K; Rugo H; Miller K; Ellis M; Shapira I; Wolff AC; Carey LA; Moy B; Groarke J; Moslehi J; Krop I; Burstein HJ; Hudis C; Winer EP; Tolaney SM
JAMA Oncol; 2016 Jan; 2(1):29-36. PubMed ID: 26539793
[TBL] [Abstract][Full Text] [Related]
23. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
Guglin M; Munster P; Fink A; Krischer J
Am Heart J; 2017 Jun; 188():87-92. PubMed ID: 28577685
[TBL] [Abstract][Full Text] [Related]
24. Reliability of Left Ventricular Ejection Fraction from Three-Dimensional Echocardiography for Cardiotoxicity Onset Detection in Patients with Breast Cancer.
Lorenzini C; Lamberti C; Aquilina M; Rocca A; Cortesi P; Corsi C
J Am Soc Echocardiogr; 2017 Nov; 30(11):1103-1110. PubMed ID: 28822666
[TBL] [Abstract][Full Text] [Related]
25. Three-dimensional speckle-tracking echocardiography for the global and regional assessments of left ventricle myocardial deformation in breast cancer patients treated with anthracyclines.
Coutinho Cruz M; Moura Branco L; Portugal G; Galrinho A; Timóteo AT; Rio P; Ilhão Moreira R; Mendonça T; Leal A; Gameiro F; Duarte Oliveira S; Luz R; Cruz Ferreira R
Clin Res Cardiol; 2020 Jun; 109(6):673-684. PubMed ID: 31559482
[TBL] [Abstract][Full Text] [Related]
26. Single Versus Standard Multiview Assessment of Global Longitudinal Strain for the Diagnosis of Cardiotoxicity During Cancer Therapy.
Thavendiranathan P; Negishi T; Coté MA; Penicka M; Massey R; Cho GY; Hristova K; Vinereanu D; Popescu BA; Izumo M; Negishi K; Marwick TH;
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1109-1118. PubMed ID: 29778856
[TBL] [Abstract][Full Text] [Related]
27. Time Trends of Left Ventricular Ejection Fraction and Myocardial Deformation Indices in a Cohort of Women with Breast Cancer Treated with Anthracyclines, Taxanes, and Trastuzumab.
Tan TC; Bouras S; Sawaya H; Sebag IA; Cohen V; Picard MH; Passeri J; Kuter I; Scherrer-Crosbie M
J Am Soc Echocardiogr; 2015 May; 28(5):509-14. PubMed ID: 25772019
[TBL] [Abstract][Full Text] [Related]
28. Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients.
Keramida K; Farmakis D; Bingcang J; Sulemane S; Sutherland S; Bingcang RA; Ramachandran K; Tzavara C; Charalampopoulos G; Filippiadis D; Kouris N; Nihoyannopoulos P
Eur J Heart Fail; 2019 Apr; 21(4):529-535. PubMed ID: 30811091
[TBL] [Abstract][Full Text] [Related]
29. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity.
Negishi K; Negishi T; Hare JL; Haluska BA; Plana JC; Marwick TH
J Am Soc Echocardiogr; 2013 May; 26(5):493-8. PubMed ID: 23562088
[TBL] [Abstract][Full Text] [Related]
30. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.
Sawaya H; Sebag IA; Plana JC; Januzzi JL; Ky B; Tan TC; Cohen V; Banchs J; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
Circ Cardiovasc Imaging; 2012 Sep; 5(5):596-603. PubMed ID: 22744937
[TBL] [Abstract][Full Text] [Related]
31. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
[TBL] [Abstract][Full Text] [Related]
32. Effect of Rosuvastatin in Preventing Chemotherapy-Induced Cardiotoxicity in Women With Breast Cancer: A Randomized, Single-Blind, Placebo-Controlled Trial.
Nabati M; Janbabai G; Esmailian J; Yazdani J
J Cardiovasc Pharmacol Ther; 2019 May; 24(3):233-241. PubMed ID: 30599756
[TBL] [Abstract][Full Text] [Related]
33. Deformation Analysis of Myocardial Layers Detects Early Cardiac Dysfunction after Chemotherapy in Bone Marrow Transplantation Patients: A Continuous and Additive Cardiotoxicity Process.
Paraskevaidis IA; Makavos G; Tsirigotis P; Psarogiannakopoulos P; Parissis J; Gkirkas K; Pessach I; Ikonomidis I
J Am Soc Echocardiogr; 2017 Nov; 30(11):1091-1102. PubMed ID: 28864152
[TBL] [Abstract][Full Text] [Related]
34. Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer.
Honda K; Takeshita K; Murotani K; Mitsuma A; Hayashi H; Tsunoda N; Kikumori T; Murohara T; Ando Y
Breast Cancer; 2017 Mar; 24(2):312-318. PubMed ID: 27234030
[TBL] [Abstract][Full Text] [Related]
35. Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA).
Reuvekamp EJ; Bulten BF; Nieuwenhuis AA; Meekes MR; de Haan AF; Tol J; Maas AH; Elias-Smale SE; de Geus-Oei LF
J Nucl Cardiol; 2016 Aug; 23(4):824-32. PubMed ID: 26048264
[TBL] [Abstract][Full Text] [Related]
36. Small benefits in trastuzumab-related cardiotoxicity.
Das M
Lancet Oncol; 2017 Jan; 18(1):e5. PubMed ID: 27956153
[No Abstract] [Full Text] [Related]
37. ABSDELL Model: Development and Internal Validation of a Risk Prediction Model of LVEF Decline in Breast Cancer Patients Treated With Trastuzumab.
Liu X; Tao L; Wang M; Li H; Xu W
Clin Breast Cancer; 2023 Jan; 23(1):23-31. PubMed ID: 36384817
[TBL] [Abstract][Full Text] [Related]
38. Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction.
Yu AF; Yadav NU; Eaton AA; Lung BY; Thaler HT; Liu JE; Hudis CA; Dang CT; Steingart RM
Oncologist; 2015 Oct; 20(10):1105-10. PubMed ID: 26240135
[TBL] [Abstract][Full Text] [Related]
39. Left Ventricular Regional Wall Motion Abnormality is a Strong Predictor of Cardiotoxicity in Breast Cancer Patients Undergoing Chemotherapy.
de Barros MVL; Macedo AVS; Sarvari SI; Faleiros MH; Felipe PT; Silva JLP; Edvardsen T
Arq Bras Cardiol; 2019 Jan; 112(1):50-56. PubMed ID: 30569947
[TBL] [Abstract][Full Text] [Related]
40. Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer.
Calvillo-Argüelles O; Abdel-Qadir H; Suntheralingam S; Michalowska M; Amir E; Thavendiranathan P
Am J Cardiol; 2020 Apr; 125(8):1270-1275. PubMed ID: 32087998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
